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Goodpasture antigen: Expression of the full-length a3(IV) Goodpasture (GP) syndrome is an autoimmune dis-
chain of collagen IV and localization of epitopes exclusively ease characterized by rapidly progressive glomerular ne-
to the noncollagenous domain. phritis and pulmonary hemorrhage [1]. Tissue injury is
Background. Tissue injury in Goodpasture (GP) syndrome
thought to be mediated by antibasement membrane anti-(rapidly progressive glomerular nephritis and pulmonary hem-
bodies reacting with the glomerular basement membraneorrhage) is mediated by antibasement membrane antibodies
that are targeted to the a3(IV) chain of type IV collagen, one and the alveolar basement membrane. The target au-
of five a(IV) chains that occur in the glomerular basement toantigen in the basement membrane is known to be the
membrane. GP antibodies are known to bind epitopes within a3(IV) chain of type IV collagen, commonly referred
the carboxyl terminal noncollagenous domain (NC1) of the
to as the “GP autoantigen” [2–4]. A knowledge of GPa3(IV) chain, termed the GP autoantigen. Whether epitopes
epitopes is important for the understanding of the etiol-also exist in the 1400-residue collagenous domain is unknown
ogy and pathogenesis of the disease and for the develop-because studies to date have focused solely on the NC1 domain.
A knowledge of GP epitopes is important for the understanding ment of therapeutic strategies.
of the etiology and pathogenesis of the disease and for the The complete primary structure of the human a3(IV)
development of therapeutic strategies. chain is known [5]. The chain is characterized by a long
Methods. A cDNA construct was prepared for the full-
collagenous domain of 1410 amino acid residues that islength human a3(IV) chain. The construct was stably trans-
interrupted by 23 short noncollagenous sequences andfected into human embryonic kidney 293 cells. The purified
by a noncollagenous (NC1) domain of 232 residues atfull-length r-a3(IV) chain was characterized by electrophoresis
and electron microscopy. The capacity of this chain for binding the carboxyl terminus. In the glomerular basement mem-
of GP antibodies from five patients was compared with that brane, the a3(IV) chain exists in a supramolecular net-
of the human r-a3(IV)NC1 domain by competitive enzyme- work along with the a4(IV) and a5(IV) chains of typelinked immunosorbent assay.
IV collagen [6]. The network is characterized by loopsResults. The r-a3(IV) chain was secreted from 293 cells as
and supercoiled triple-helical molecules that are stabi-a single polypeptide chain that did not spontaneously undergo
assembly into a triple-helical molecule. An analysis of GP- lized by disulfide cross-links.
antibody binding to the full-length r-a3(IV) chain showed bind- The study of GP-autoantibody binding has been fo-
ing exclusively to the globular NC1 domain. cused on epitopes in the NC1 domain of the a3(IV)
Conclusion. The full-length human a3(IV) chain possesses chain [2–4]. Whether epitopes also exist within the 1400-the capacity to bind GP autoantibodies. The epitope(s) is found
residue collagenous domain is unknown, as the a3(IV)exclusively on the nontriple-helical NC1 domain of the a3(IV)
chain is not amenable to isolation and purification fromchain, indicating the presence of specific immunogenic proper-
ties. The a3(IV) chain alone does not spontaneously undergo tissue as the NC1 domain. The a3(IV)NC1 domain was
assembly into a triple-helical homotrimeric molecule, sug- initially isolated as a 28 kDa protein from basement
gesting that coassembly with either the a4(IV) and/or the membranes by collagenase digestion. Its novel identity
a5(IV) chain may be required for triple-helix formation.
was established based on molecular properties and its
capability to bind GP autoantibodies [2–4, 7, 8]. Subse-
quently, it was confirmed by molecular cloning [9–11].Key words: Goodpasture syndrome, recombinant protein, type IV col-
lagen, autoimmune disease, NC1 domain. The discovery of homologous NC1 domains that corre-
spond to the a4(IV), a5(IV), and a6(IV) chain [12–14]Received for publication May 28, 1998
raised the question of whether epitopes also exist withinand in revised form October 14, 1998
Accepted for publication October 14, 1998 the NC1 domains of other members of the type IV family
of six a(IV) chains. In a recent study of 58 GP patient 1999 by the International Society of Nephrology
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Table 1. Primers used in PCR amplification reactions published sequence [5]. Nhe I and Cla I restriction en-
zyme sites were introduced at the 59 and 39 ends, respec-Product Primer sequences
tively. The cDNA was ligated into a modified pRC-X1st PCR A1 59-GGCTCTGAGCTCTCTCCCACCATG-39
of cDNA B1 59-ACAATCACCGTATGAGCAGTGCC-39 expression vector into Nhe I and Cla I sites. The construc-
2nd PCR A2 59-CGCGCTAGCCAAGGGTTGTGTCTG tion of this vector was based on the pRC/AC7 vector
of cDNA TAAAGAC-39
(kindly provided by Dr. Ernst Po¨schl, Erlangen, Ger-B2 59-TCTATCGATGCTTCAGTGTCTTTT
CTTCATG-39 many), containing the signal peptide of BM40 down-
Correction A3 59-CCCTGGCACACTTAAGATTAT stream of the cytomegalovirus (CMV) promoter [17].
fragment CTCC-39
The DNA sequence encoding the FLAGE peptide (DYB3 59-TCTATCGATGCTTCAGTGTCTTTT
CTTCATG-39 KDDDDK) and additional restriction enzyme sites (Fig.
1st PCR A4 59-CAAGCTAGCGGCCGCTCGAGAT 1) for subcloning were introduced by primers (Table 1).
of vector GCATCTAGAGGGCCC-39
The resulting pRC-X/a3(IV) construct was checked byB4 59-GCCGCTAGCTTGTCATCGTCGTC
CTTGTAGTCGGCTAGTGGGGCTGC restriction enzyme analysis and DNA sequencing. One
CAGAGCCCT-39 PCR-related single-base mutation (T4968→C) was cor-
2nd PCR A5 59-AGCTCTAGAGTCATCGATGTTA
rected by cutting the construct with Afl I and Cla I restric-of vector ACCGCGGGCCCTATTCTATAGTGTC-39
B5 59-CCCTCTAGATGCATCTCGAGC tion enzymes and replacing the fragment with a new
GGC-39 fragment generated by PCR amplification (Table 1).
Cell cultures and transfections
Human embryonic kidney 293 cells were grown in
Dulbecco’s modified Eagle’s medium/F12 medium (Sig-sera, the a3(IV)NC1 domain was found to be the com-
ma Chemicals, St. Louis, MO, USA) medium containingmon autoantigen [15]. The antibodies of all patients re-
5% fetal bovine serum and 50 mg/ml ascorbic acid phos-acted with the a3(IV)NC1 domain (85% exclusively).
phate (Wako, Richmond, VA, USA). Transfections wereAdditional limited reactivity with the a1(IV)NC1 and
done by using SuperFect reagent (Qiagen, Chatsworth,a4(IV)NC1 was found in 15 and 3% of the patients,
CA, USA) and 5 mg of pRC-X/a3(IV) construct. Selec-respectively. In a study of 10 patients, using E. coli fusion
tion of transfected cells was started with 250 mg/ml G418proteins of the six a(IV)NC1 domains, all showed reac-
(GIBCO, Grand Island, NY, USA) two days after trans-tivity to the a3(IV)NC1 domain, and several sera showed
fection. Resistant clones were isolated and expanded.additional reactivity to a2(IV), a4(IV), or a6(IV)NC1
Stably transfected clones were screened for protein ex-domains [16]. Overall, the results in vitro establish that
pression from serum-free medium by slot blotting and/among the six a(IV)NC1 domains, the a3(IV)NC1 do-
or Western blotting using anti-FLAG antibody (Kodak,main is the primary target for GP antibodies.
Rochester, NY, USA).In this study, a cDNA construct encoding the full-
length a3(IV) chain was successfully made, character-
Protein purificationized, and expressed in human embryonic kidney 293
Medium from stably transfected 293 cell cultures wascells. The expressed chain allows for the determination
collected after 48 hours. Protease inhibitors ethylenedi-of binding of GP autoantibodies and localization of epi-
aminetetraacetic acid (EDTA, 1 mm) and phenylmethyl-topes. The results show that binding of GP autoantibod-
sulfonyl fluoride (PMSF, 2 mm) were then added, andies is exclusively localized to the NC1 domain of the
the medium was stored at 2208C. The medium was madenontriple-helical, full-length a3(IV) chain, indicating the
0.2 m with NaCl before passing through an anti-FLAGpresence of specific immunogenic properties in this re-
affinity chromatography column (Kodak). The boundgion. The results also suggest that the triple-helical as-
FLAG-tagged recombinant a3(IV) chain was elutedsembly of the a3(IV) chain may require coassembly with
from the column by competing FLAG-peptide (Kodak)either the a4(IV) chain, the a5(IV) chain, or both.
at a concentration of 100 mg/ml in Tris-buffered saline.
Protein samples were concentrated by ultrafiltration
METHODS (Amicon, Beverly, MA, USA) and were stored at 2708C.
DNA construction
SDS-PAGE and Western blotsAn approximately 5.0 kb full-length a3(IV) cDNA
Sodium dodecyl sulfate-polyacrylamide gel electro-(nucleotides 246 to 5174 according to the published se-
phoresis (SDS-PAGE) was carried out in 4 to 15% linearquence, GenBank X80031) was generated by nested
gradient gels [18] and was stained with Coomassie Bril-polymerase chain reaction (PCR) amplification from hu-
liant Blue R250 or transferred onto nitrocellulose mem-man Marathon kidney cDNA library (Clontech, Palo
branes. Anti-FLAG M2 (Kodak) and monoclonal anti-Alto, CA, USA) by using Klentaq polymerase (Clon-
tech) and primers (Table 1) designed according to the a3(IV)NC1, Mab3 (Wieslab Ab, Sweden) antibodies
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Fig. 1. Schematic showing the pRC/a3(IV) construct. The full-length a3(IV) cDNA was generated by polymerase chain reaction (PCR) and
subcloned into Nhe I and Cla I restriction sites in the pRC-X expression vector, which was modified by adding BM40 signal peptide, FLAG
peptide, and additional restriction sites.
were used in Western blots under conditions described Expression of recombinant human a2(IV)NC1 and
a3(IV)NC1 domainspreviously [8].
Human r-a2(IV)NC1 and r-a3(IV)NC1 proteins were
Enzyme digestions expressed in human embryonic kidney 293 cells and puri-
fied as described earlier [19].For collagenase digestion, the purified r-a3(IV) chain
was ethanol precipitated and suspended into 0.15 m
Patient seraNaCl, 50 mm Tris-HCl, pH 7.4, containing 5 mm CaCl2,
1 mm N-ethylmaleimide, and 2 mm phenylmethylsulfonyl Aliquots of plasmapheresis fluid of five GP patients
were used in enzyme-linked immunosorbent assays. GP-fluoride. Bacterial collagenase was added at a 1:10 en-
IgG antibody (GP-1) sera was described earlier [8].zyme/protein ratio, and digestion was performed at
1378C for 18 hours. For pepsin digestion, recombinant
Affinity chromatography ofprotein was suspended in 0.5 m acetic acid and was incu-
Goodpasture autoantibodiesbated with pepsin at 1:10 enzyme/protein ratio for 18
hours at 148C. After enzyme digestion, proteins were Recombinant a3(IV)NC1 domain at a concentration
of 0.5 mg/ml was coupled to Affigel-10 matrix (Bio-Rad,ethanol precipitated and analyzed by SDS-PAGE.
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Table 2. Amino acid changes compared to the published primary
structure of a3(IV) chain [5]
Base paira Amino acid
A 375 → C Thr-72 → Pro
T 583 → C Leu-141 → Pro
A 646 → G Glu-162 → Gly
T 1360 → A Ile-400 → Lys
G 1486 → T Gly-442 → Val
C 1882 → T Pro-574 → Leu
C 2903 → G His-914 → Gln
T 3193 → G Leu-1011 → Arg
a Numbering is based on the sequence in GenBank, X80031
Richmond, CA, USA) according to the manufacturer’s
protocol. Two milligrams of GP-1 was applied to the
column. Unbound material was collected, and the bound
material was eluted with 3 m potassium thiocyanate
(KSCN). Both fractions were concentrated by Centri-
con-10 spin concentrators and were used in competitive
ELISA assays.
Competitive enzyme-linked immunosorbent assay
Fifty nanograms of the r-a3(IV)NC1 or 200 ng of the
r-a3(IV) chain were coated on 96-well plates (Nunc,
Naperville, IL, USA) in 200 ml of 50 mm sodium carbon-
ate, pH 9.5, coating buffer. Plates were washed with 150 Fig. 2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) patterns of purified r-a3(IV) chain. The r-a3(IV) chainmm NaCl and 0.05% Tween 20 buffer (washing buffer)
was purified from the culture medium by using FLAG-affinity chroma-and were blocked with 1% casein in 50 mm Tris-HCl, tography. Purified samples were run on 4 to 15% gradient gels under
pH 7.4. Different concentrations of the r-a3(IV) chain, nonreducing (A) and reducing (B) conditions and were stained with
Coomassie Blue. Without reduction, the r-a3(IV) chain migrated as athe r-a3(IV)NC1, the r-a2(IV)NC1, and albumin were
double band with Mr . 200,000. After reduction with 20 mm dithiothrei-preincubated with 1:100 dilution of five different GP tol, the chain appeared as a single band, Mr approximately 250,000.
sera, 1:25 dilution of unbound GP-IgG, or 1:50 dilution
of bound GP-IgG in 50 mm Tris-HCl, pH 7.4, buffer
before adding to the coated wells. Alkaline phosphatase-
conjugated anti-human IgG at a dilution of 1:3000 was CA, USA) after hydrolysis was performed by the Bio-
Core Facility at University of Kansas Medical Center.used as a secondary antibody, with disodium p-nitro-
phenyl phosphate as a substrate. Plates were read at 410
nm in a Dynatech MR 400 plate reader.
RESULTS
Preparation of a full-length construct of the humanElectron microscopy
a3(IV) chainThe recombinant a3(IV) chain was diluted with 0.15
m ammonium bicarbonate buffer to a concentration of The cDNA encoding a full-length human a3(IV) chain
was generated from a kidney cDNA library by a nested50 mg/ml, and an equal volume of glycerol was added.
The sample was then sprayed onto freshly cleaved mica PCR amplification strategy. This strategy was selected to
avoid several modifications steps involved in generatingsheets. Rotating samples were shadowed at a 5 to 6
degree angle with 0.9 nm platinum and were then coated full-length cDNA from the original partial cDNA clones
[5], which lacked suitable restriction enzyme sites forwith carbon deposited at a 908 angle. The replicas were
viewed with a JEOL JEM 100CX II electron microscope subcloning. The full-length a3(IV) cDNA was then li-
gated into a pRC-X expression vector containing a(JEOL, Tokyo, Japan), photographed at a magnification
of 319,000, and the prints of the negatives were enlarged FLAG sequence for affinity purification (Fig. 1) and
sequenced. Nine sequence variations were found in thefivefold.
full-length a3(IV) cDNA that differed from the pub-
Amino acid analysis lished sequence [5] and would encode variations in the
amino acid sequence. The base pair changes were con-Amino acid analysis of the r-a3(IV) chain and mouse
type IV collagen (Becton Dickinson, Mountain View, firmed by repeating cDNA amplification from the same
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Fig. 3. Western blot analysis of the full-length and collagenase-digested r-a3(IV) chain. The r-a3(IV) chain and its collagenase digestion products
were run on 4 to 15% gradient gels and were blotted with monoclonal antibody against a3(IV)NC1 (A) and Goodpasture antibodies (GP-1; B).
Lane 1, molecular weight standard (Gibco); lane 2, r-a3(IV) chain; lane 3, collagenase-digested r-a3(IV) chain; and lane 4, r-a3(IV)NC1.
Table 3. Amino acid analysis of r-a3(IV) chain one to four residues. The remaining sequence change
(proline for serine 1603) most likely reflected a PCR-Amino acid % in a3(IV) Hydroxylated %
related mutation that occurred at a highly conservedHyL 2.62 28
Lys 6.70 amino acid position of the NC1 domain. This mutation
was corrected by inserting a PCR-generated fragmentHyP 10.28 48
Pro 11.13 with the correct sequence.
Expression and characterization of the r-a3(IV) chain
The full-length a3(IV) construct was stably transfected
library and by subsequent sequencing. The original
into human embryonic kidney 293 cells. Cell clones werecDNA clones (PCR1, AK20, AK12, and AK1) on which
tested for the r-a3(IV) chain expression by slot and West-the published a3(IV) sequence is based were then rese-
ern blotting using anti-FLAG antibody. The r-a3(IV)quenced. Eight of nine variations in questions were
chain was expressed as a fusion protein containing afound to be present in original clones. Hence, the pub-
short FLAG peptide (DYKDDDDK) at the amino ter-lished a3(IV) sequence contains eight incorrect base
minus that allowed purification of recombinant proteinpairs that resulted in incorrect amino acid residues (Ta-
by single-step FLAG-affinity chromatography (Kodak).ble 2). Five of the sequencing errors were in the collage-
The r-a3(IV) chain appeared as a double band, withnous domain in Y positions, one in an X position of the
a Mr . 200,000, as observed by SDS-PAGE under nonre-Gly X-Y collagenous repeat sequence, and two were in
ducing conditions, and after reduction of the disulfideinterruptions of the collagenous sequence. The latter two
bonds as a single band with Mr 5 approximately 250,000were a substitution of glycine for glutamic acid 646 in
(Fig. 2). The higher band seen on the gel under nonreduc-interruption I, and a substitution of valine for glycine
1486 that increased the length of interruption VIII from ing conditions probably represents disulfide-linked di-
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Fig. 4. Rotary shadowing electron microscopy of the r-a3(IV) chain. The r-a3(IV) chain exists mainly in nontriple-helical form, and only the
globular NC1 domains were visible by electron microscopy (A and B). In a few cases, rod-like extensions from the globular domains, representing
triple-helical domains, were observed (C and D).
mers. The r-a3(IV) chain is slightly larger in size than used as a control in the analysis, and it revealed 65% and
52% hydroxylation of the proline and lysine residues,the recombinant mouse a1(IV) and a2(IV) chains ex-
pressed in Chinese hamster ovary (CHO) cells [20], respectively. The underhydroxylation of the recombi-
nant protein might be a result of overexpression of thewhich had Mr 5 185,000 and 170,000, respectively. The
size of the r-a3(IV) chain was estimated to be 1767 resi- recombinant protein due to the strong cytomegalovirus
promoter.dues based on the electrophoretic mobility of standard
proteins containing a known number of residues [21]. Rotary shadowing electron microscopy of the r-a3-
(IV) chain revealed a high number of globular domainsAfter collagenase digestion, the r-a3(IV) chain yielded
the a3(IV)NC1 domain with Mr 5 28,000. The size of (NC1), which appeared in different sizes (Fig. 4). This
indicates that the NC1 domain forms some aggregatesthis collagenase digestion product is slightly smaller than
that of the recombinant a3(IV)NC1 on SDS-PAGE (Fig. such as dimers. Rod-like extensions to globular domains,
representing triple-helical domains, were observed in3) because the latter contains a FLAG peptide at the
amino terminus. The full-length a3(IV) chain and its only a few cases. The length of these triple helices was
determined by the NIH Image program, and it variedNC1 domain were both recognized by monoclonal anti-
body against a3(IV)NC1, as well as by the affinity-puri- between 340 and 380 nm, coming close to the lengths of
type IV collagen molecules in native basement mem-fied GP autoantibody (GP-1; Fig. 3 A, B, respectively),
establishing the identity and purity of the expressed full- branes. Pepsin digestion of expressed recombinant pro-
tein did not reveal any pepsin-resistant material (datalength r-a3(IV) chain. Amino acid analysis of the recom-
binant a3(IV) chain showed that approximately 48% of not shown), indicating that the amount of triple-helical
molecules, as observed by rotary shadowing electronthe proline residues and 28% of the lysine residues were
hydroxylated (Table 3). Mouse type IV collagen was microscopy, is very low. Presumably, these triple-helical
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Fig. 5. Assessment of the binding capacity of Goodpasture (GP) antibodies to r-a3(IV) chain relative to r-a3(IV)NC1 by competitive enzyme-
linked immunosorbent assay. The r-a3(IV) chain (A and C) and the r-a3(IV)NC1 (B and D) were coated on the plates. GP antibodies from one
patient (GP-1) were preincubated with various concentrations of the r-a3(IV) chain and the r-a3(IV)NC1 before adding them to the coated wells
(A and B), and five GP sera were preincubated with the r-a3(IV) chain and r-a3(IV)NC1 at a concentration of 80 nm before adding them to the
coated wells (C and D). r-a2(IV)NC1 and albumin were used as controls. Color development was measured at 410 nm.
molecules represent a3(IV) homotrimers because no en- The amount of inhibition was also determined for several
dogenous expression of a4(IV) or a5(IV) chains was GP sera (Fig. 5 C–D), and the results showed virtually
detected by Western blot analysis (data not shown). complete inhibition when the full-length chain was com-
pared with the r-a3(IV)NC1 domain and vice versa.
Goodpasture autoantibody binding to the These results demonstrate that the epitopes for GP auto-
r-a3(IV) chain
antibodies are exclusively localized on the NC1 domain
The capacity of the human full-length r-a3(IV) chain of the nontriple-helical a3(IV) chain.
to bind GP autoantibodies was tested by competitive To verify this conclusion further, antibodies from one
ELISA and compared with that of the r-a3(IV)NC1 do- serum were absorbed onto an affinity column composed
main. The r-a3(IV)NC1 domain has a similar binding
of r-a3(IV)NC1. The bound and unbound fractions fromcapacity of GP autoantibodies as the native a3(IV)NC1
this column were analyzed for their capacity to bind themonomers isolated from tissues (Boutaud A, Gunwar S,
full-length chain (Fig. 6 A–D). The bound antibodies,Singh N, Netzer K-O, Sado Y, Ninomiya Y, Noelken
directed against the a3(IV)NC1 domain, showed identi-ME, Hudson BG, manuscript in preparation). The
cal inhibition against the full-length r-a3(IV) chain orr-a3(IV)NC1 completely inhibited binding of GP auto-
the r-a3(IV)NC1 domain, whereas the unbound fractionantibodies to the full-length chain over a wide range of
contained no antibody reactivity against either the full-concentrations (Fig. 5A). Likewise, the full-length chain
completely inhibited binding to r-a3(IV)NC1 (Fig. 5B). length chain or the NC1 domain. These results further
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Fig. 6. The assessment of binding capacity of Goodpasture (GP) antibodies to the r-a3(IV) chain and the r-a3(IV)NC1 domain by binding of
GP antibodies by r-a3(IV)NC1 affinity column. The r-a3(IV) chain (A and C) and r-a3(IV)NC1 (B and D) were coated on the plate. GP antibodies
(GP-1), which bound to the r-a3(IV)NC1 affinity column (A and B) and unbound antibodies (C and D) were preincubated with various concentrations
of r-a3(IV) chain, r-a3(IV)NC1, r-a2(IV)NC1, and albumin before adding them to the coated wells. Color development was measured at 410 nm.
demonstrate that the epitope for GP autoantibodies are the expressed chains exist mainly in nontriple-helical
form. The triple-helix formation is believed to be drivenexclusively directed to the a3(IV)NC1 domain.
by an interaction near the C-terminus; therefore, it is
unlikely that the expression of the FLAG peptide at the
DISCUSSION
N-terminus was interfering the trimer formation. The
In this study, the full-length human r-a3(IV) chain slight underhydroxylation of the recombinant protein in
was expressed in 293 cells for the first time. As a collateral 293 cells, likely a result of the overexpression of the
result of the assembly and sequencing of full-length protein due to the strong CMV promoter, could be a
a3(IV) cDNA, it was found that the previously published reason for the absence of trimeric molecules. On the
sequence [5] was incorrect in eight positions. The errors other hand, the report of expression of collagen X ex-
illustrate the difficulty of working with long DNA se- pressed in the same cell line showed a formation of triple-
quences of low complexity and point to cautious inter- helical molecules and aggregates ranging from dimers to
pretation of sequence data. multimers despite the underhydroxylation [23].
Protein expression of the a3(IV) chain in eukaryotic In a study with recombinant expression of mouse
293 cells was feasible. Other examples for the successful a1(IV) and a2(IV) chains in CHO cells, it was noted
expression of recombinant collagen molecules in 293 that a1(IV) chains alone also were not able to form
cells include type V and X collagen chains and their triple-helical molecules, but required coexpression of the
assembly into triple-helical molecules [22, 23]. However, a2(IV) chain [20]. In the case of the a3(IV) chain, it
in the case of the r-a3(IV) chain, only a very small frac- may be speculated that coexpression of the a4(IV)
tion of chains formed triple-helical molecules, as ob- and/or the a5(IV) chain is likely required for triple-
served by rotary shadowing electron microscopy. Ac- helix formation. This speculation is supported by the
observations that (a) the a3(IV), a4(IV), and a5(IV)cordingly, no pepsin resistance was found, indicating that
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ST: Complete primary structure of the human a3(IV) collagenchains in vivo coexist in a supramolecular network in
chain: Coexpression of the a3(IV) and a4(IV) collagen chains in
basement membranes [6] and (b) mutations in the human tissues. J Biol Chem 269:23013–23017, 1994
6. Gunwar S, Ballester F, Noelken M, Sado Y, Ninomiya Y, Hud-a5(IV) chain in patients with Alport syndrome cause
son BG: Glomerular basement membrane: Identification of a noveldisassembly of the a3(IV), a4(IV), and a5(IV) network
disulfide-crosslinked network of a3, a4 and a5 chains of type IV
[24–28]. Ultimately, the assembly of cDNA constructs collagen and its implications for the pathogenesis of Alport syn-
drome. J Biol Chem 273:8767–8775, 1998of full-length a4(IV) and a5(IV) chains and their coex-
7. Butkowski RJ, Langeveld JP, Wieslander J, Hamilton J, Hud-pression with other chains will be required to answer
son BG: Localization of the Goodpasture epitope to a novel chain
the ambitious question of the code for chain selection of basement membrane collagen. J Biol Chem 262:7874–7877, 1987
8. Gunwar S, Ballester F, Kalluri R, Timoneda J, Chonko AM,and association.
Edwards SJ, Noelken ME, Hudson BG: Glomerular basementThe expression of the full-length a3(IV) chain pro-
membrane: Identification of dimeric subunits of the noncollage-
vided a novel strategy to determine whether epitopes for nous domain (hexamer) of collagen IV and the Goodpasture anti-
gen. J Biol Chem 266:15318–15324, 1991GP autoantibodies are localized to the long collagenous
9. Morrison KE, Germino GG, Reeders ST: Use of the polymerasedomain in addition to the NC1 domain. Our results with
chain reaction to clone and sequence a cDNA encoding the bovine
autoantibodies from five GP patients clearly establish a3 chain of type IV collagen. J Biol Chem 266:34–39, 1991
10. Morrison KE, Mariyama M, Yang-Feng TL, Reeders ST: Se-that the epitopes are exclusively localized to the NC1
quence and localization of partial cDNA encoding the human a3domain of the nontriple-helical form of the a3(IV) chain.
chain of type IV collagen. Am J Genet 49:545–554, 1991
Whether the collagenous domain or the NC1 domain 11. Turner N, Mason PJ, Brown R, Fox M, Povey S, Rees A, Pusey
CD: Molecular cloning of the human Goodpasture antigen demon-possess additional epitopes formed by the assembly of
strates it to be the alpha 3 chain of type IV collagen. J Clin Investthe a3(IV), a4(IV), and a5(IV) chains in a triple-helical
89:592–601, 1992
network, involving complex interactions between chains, 12. Gunwar S, Saus J, Noelken ME, Hudson BG: Glomerular base-
ment membrane: Identification of a fourth chain, a4, of type IVtriple helices, and NC1 domains, remains unknown.
collagen. J Biol Chem 265:5466–5469, 1990Clearly, however, epitopes in the a3(IV)NC1 domain
13. Hostikka SL, Eddy RL, Byers MG, Hoyhtya M, Shows TB,
are sufficient to induce the formation of autoantibodies Tryggvason K: Identification of a distinct type of type IV collagen
a chain with restricted kidney distribution and assignment of itsthat mimic virtually all of the characteristics of the patho-
gene to the locus of X chromosome-linked Alport syndrome. Procgenic human GP autoantibodies [19, 29, 30]. Hence, these
Natl Acad Sci USA 87:1606–1610, 1990
findings suggest that a potential therapeutic strategy for 14. Zhou J, Mochizuki T, Smeets H, Antignac C, Laurila P, de
Paepe A, Tryggvason K, Reeders ST: Deletion of the pairedthe selective removal of human GP autoantibodies from
a5(IV) and a6(IV) collagen genes in inherited smooth muscleplasma is the use of affinity chromatography using the
tumors. Science 261:1167–1169, 1993
human r-a3(IV)NC1 domain and not the entire a3(IV) 15. Kalluri R, Wilson CB, Weber M, Gunwar S, Chonko AM,
Neilson EG, Hudson BG: Identification of the a3 chain of type IVchain. The feasibility of affinity chromatography using
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